Strong Or Moderate Cyp3a Inducers Interactions

Concomitant use decreases quizartinib systemic exposure, which may reduce VANFLYTA efficacy. Concomitant use should be avoided.

Source: NLP:quizartinib

Strong or moderate CYP3A inducers may decrease exposure of vonoprazan and clarithromycin, reducing effectiveness of VOQUEZNA TRIPLE PAK.

Source: NLP:vonoprazan fumarate and amoxicillin